Artia Global Partners »

Apellis Pharmaceuticals shares owned by Artia Global Partners

Quarter-by-quarter ownership of Apellis Pharmaceuticals (APLS) shares owned by Artia Global Partners from 13F filings

Historical chart of Artia Global Partners investment in Apellis Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Apellis Pharmaceuticals held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Apellis Pharmaceuticals by Artia Global Partners

Quarter filed Position value Share count Share price at filing
2023-06-30 $9.4M 103k 91.10

More positions owned by Artia Global Partners

Insmed Com Par $.01 (INSM)
Argenx Se Sponsored Adr (ARGX)
Soleno Therapeutics (SLNO)
Verona Pharma Sponsored Ads (VRNA)
Uniqure Nv SHS (QURE)
Merus N V (MRUS)
Proshares Tr Ii Ultra Gold (UGL)
Eli Lilly & Co. (LLY)
Vertex Pharmaceuticals Incorporated (VRTX)
Abivax Sa Sponsored Ads (ABVX)
Trevi Therapeutics (TRVI)
Boston Scientific Corporation (BSX)
Alnylam Pharmaceuticals (ALNY)
Quest Diagnostics Incorporated (DGX)
Astrazeneca Sponsored Adr (AZN)

View all positions for Artia Global Partners

Top funds holding Apellis Pharmaceuticals

venBio Select Advisor
Vanguard Group
Wellington Management Company
Deep Track Capital
BlackRock
AQR Capital Management
Jennison Associates
State Street Corporation
EcoR1 Capital
UBS Group
Suvretta Capital Management
Polar Capital Holdings
Siren
OrbiMed Advisors
Geode Capital Management

View all funds holding Apellis Pharmaceuticals